Global Atherosclerosis Clinical Trials Rise Due to Higher Disease Incidences, H1 Review Till 2017


Published on : Jun 15, 2017

Albany, New York, June 15, 2017: As per the findings of a latest study, growing incidence of heart attacks due to atherosclerosis or coronary heart disease is expected to increase demand for atherosclerosis treatment products. To overcome this issue, there are many clinical trials are in process. Market Research Hub (MRH) has recently published a latest market study to its vast repository, which is titled as “Atherosclerosis Global Clinical Trials Review, H1, 2017”. This 480-pages study provides an overview of Atherosclerosis clinical trials scenario, provides top-line data relating to the clinical trials. Furthermore, it includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

Atherosclerosis is a slow, progressive disease that may start as early as childhood. However, the disease has the potential to progress quickly. Atherosclerosis is a contraction of the arteries caused by a buildup of plaque. The plaque clogs up the artery, disrupting the flow of blood around the body. This potentially causes blood clots that can result in life-threatening conditions such as heart attack, stroke and other cardiovascular diseases. It’s also called arteriosclerosis or hardening of the arteries. It has been also analyzed that treatment for arteriosclerosis includes a healthy diet, exercise and medication to control or possibly reverse patient’s condition.

Geographically, regions highlighted in the report include Asia-Pacific, North America, MEA, Europe, Central and South America. Top five countries contributing to clinical trials in the above-mentioned regions are also well described in the report. The research finds that the absence of definitive treatment, side effects and limited efficacy of the drugs available in the market and dependency in symptom based treatment in several cases are expected to hamper revenue growth of the atherosclerosis market in the coming years.

Latest clinical trials news on Atherosclerosis are also outlined. The guide covers the descriptive pharmacological achievement of the therapeutics, its complete research & development history along with latest news & press releases obtained from company/university sites and industry-specific third party resources. Furthermore, it covers emerging therapies for Atherosclerosis in active clinical development stages including early and late stage clinical trials. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc. across the globe.

The study report also features investigational drugs from across the globe. The treatment options for CAD patients are drugs such as Lipitor (atorvastatin calicium), Crestor (rosuvastatin calcium), Angiomax (bivalirudin), Plavix (clopidogrel bisulfate), Effient (prasugrel), Norvasc (amlodipine) and Altace (ramipril).

At last, the report also describes the details of companies Involved in therapeutics development along with their major and minor projects.

Click here to get more info with TOC in a PDF Formathttp://www.marketresearchhub.com/enquiry.php?type=S&repid=1135713

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-518-621-2074

+1-866-997-4948US Toll Free

Email : sales@marketresearchhub.com

Back To Top